Focus keyword: eu mdr vs ivdr blood cell counter classification
Theme: Regulation & Compliance
Think of IVDD as the old map where many roads were unmarked—and IVDR as the new map that painted in every route, then added tolls you never budgeted for.
Under the old IVDD, many hematology analyzers and their reagents sat in lower-risk self-declared lists. IVDR reclassified in-vitro diagnostics into four risk classes (A-D) based on individual risk and public-health impact, pulling countless blood cell counters and their consumables under Notified Body oversight for the first time. That reclassification is why a device you have imported for years suddenly needs a certificate, clinical data and a QMS audit it never had before.
Why the classification shifted
A CBC analyzer that can support clinical decisions on anemia, infection or leukaemia monitoring is no longer a ’self-certifiable’ list product under the new logic. The shift reflects a deliberate policy decision to close the gap the IVDD era left in public-health surveillance.
What changed operationally
Manufacturers and importers now face higher evidence demands, mandatory performance evaluations and post-market surveillance obligations. Distributors may need to update registrations, and a device with an expired certificate cannot be placed on the market even if it was fine under old rules.
What to do now
Verify the new classification of every model you carry, confirm the certificate covers analyzer and reagents together, and get a dated transition plan from your supplier. The rules do not grandfather devices forever—the certificate is the new currency.
For a practical example in this space, see the RunMei diagnostic products.
Explore the RunMei Health.
Explore the OEM/ODM manufacturing partner.
As a next step, review the contact our analyzer specialists.
Why This Matters: Authoritative Context
Regulatory context is grounded in primary sources: the EU In Vitro Diagnostic Regulation 2017/746 (IVDR) defines the transition and classification duties the industry tracks, the U.S. FDA’s 510(k) and De Novo pathways govern US market access under 21 CFR Part 820, and ISO 15189 and ISO 13485 set the quality and laboratory-management benchmarks referenced throughout. For WHO Prequalification, the WHO In Vitro Diagnostics and Laboratory Technology programme publishes the specifications and performance requirements that prequalification assessments apply. Consulting these primary texts keeps a sourcing or validation decision honest and defensible.
